Implications of cytochrome P450 interactions when prescribing medication for hypertension

被引:87
作者
Flockhart, DA [1 ]
Tanus-Santos, JE
机构
[1] Indiana Univ, Sch Med, Dept Med, Wishard Hosp, OPW 320 1001 W 10th St, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA
关键词
D O I
10.1001/archinte.162.4.405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.
引用
收藏
页码:405 / 412
页数:8
相关论文
共 87 条
  • [61] FACTORS AFFECTING THE ABSOLUTE BIOAVAILABILITY OF NIFEDIPINE
    RASHID, TJ
    MARTIN, U
    CLARKE, H
    WALLER, DG
    RENWICK, AG
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (01) : 51 - 58
  • [62] CALCIUM-ANTAGONISTS DRUG-INTERACTIONS OF CLINICAL-SIGNIFICANCE
    ROSENTHAL, T
    EZRA, D
    [J]. DRUG SAFETY, 1995, 13 (03) : 157 - 187
  • [63] The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans
    Sandstrom, R
    Knutson, TW
    Knutson, L
    Jansson, B
    Lennernas, H
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (02) : 180 - 189
  • [64] An interaction study with cimetidine and the new angiotensin II antagonist valsartan
    Schmidt, EK
    Antonin, KH
    Flesch, G
    Racine-Poon, A
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (06) : 451 - 458
  • [65] EFFECT OF CIMETIDINE OR RANITIDINE ADMINISTRATION ON NIFEDIPINE PHARMACOKINETICS AND PHARMACODYNAMICS
    SCHWARTZ, JB
    UPTON, RA
    LIN, ET
    WILLIAMS, RL
    BENET, LZ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) : 673 - 680
  • [66] Contraindicated use of cisapride - Impact of food and drug administration regulatory action
    Smalley, W
    Shatin, D
    Wysowski, DK
    Gurwitz, J
    Andrade, SE
    Goodman, M
    Chan, KA
    Platt, R
    Schech, SD
    Ray, WA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (23): : 3036 - 3039
  • [67] RANITIDINE AND CIMETIDINE - DRUG-INTERACTIONS WITH SINGLE DOSE AND STEADY-STATE NIFEDIPINE ADMINISTRATION
    SMITH, SR
    KENDALL, MJ
    LOBO, J
    BEERAHEE, A
    JACK, DB
    WILKINS, MR
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (03) : 311 - 315
  • [68] Influence of hydroxychloroquine on the bioavailability of oral metoprolol
    Somer, M
    Kallio, J
    Pesonen, U
    Pyykkö, K
    Huupponen, R
    Scheinin, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (06) : 549 - 554
  • [69] GRAPEFRUIT JUICE AND CIMETIDINE INHIBIT STEREOSELECTIVE METABOLISM OF NITRENDIPINE IN HUMANS
    SOONS, PA
    VOGELS, BAPM
    ROOSEMALEN, MCM
    SCHOEMAKER, HC
    UCHIDA, E
    EDGAR, B
    LUNDAHL, J
    COHEN, AF
    BREIMER, DD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (04) : 394 - 403
  • [70] Stanaszek W F, 1978, Hosp Pharm, V13, P255